title: [Expressions of EOS and COX-2 in nasal polyps in patients with aspirin triad syndrome and its significance].
abstract: OBJECTIVE
  To explore the regulatory role of COX-2 and aggregation of EOS in the pathogenesis of Aspirin triad syndrome.
  
  
  METHODS
  There were 34 patients with ST (group 1), 30 patients with chronic sinusitis and nasal polyps and asthma (group 2), 30 patients with sinusitis (control group). Nasal polyps of 94 patients were obtained in endoscopic sinus surgery,HE staining and immunohistochemical SP staining were performed to detect the distribution of eosinophils(EOS) and the expression of COX-2. Statistical analysis was performed using the SPSS software and then the relationship between their expression and distribution with clinical pathology and pathogenesis was analyzed.
  
  
  RESULTS
  EOS infiltrated extensively in nasal polyps, and EOS counts in these groups were 80.02 +/- 6.11, 76.62 +/- 5.22, 65.97 +/- 4.78,respectively. The difference between ST group, ATA group and control group are significant (P < 0.05), no significant difference between ST group and ATA group. COX-2 in the nasal polyps was mainly expressed in submucosal glands, glandular epithelial cells, epithelial cells, endothelial cells and EOS in interstitium. The positive cell count were 88.13 +/- 6.26, 89.46 +/- 5.97, 91.22 +/- 4.11, respectively. There was significant difference (P < 0.05) between ST group and control group. No significant difference (P > 0.05) was found between ATA group and control group,ST group and ATA group.
  
  
  CONCLUSIONS
  The difference of EOS infiltration in patients with ST may be associated with an inflammatory response underlying specific clinical manifestations after exposure to non-steroidal anti-inflammatory drugs, and the difference of COX-2 expression in patients with ST may be related to the conversion of metabolic pathway of arachidonic acid and the formation of nasal polyps.
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
authors.forename: Huajing
authors.initials: H
authors.lastname: Li
authors.forename: Zhigui
authors.initials: Z
authors.lastname: Shan
authors.forename: Bowei
authors.initials: B
authors.lastname: Wang
authors.forename: Lizhong
authors.initials: L
authors.lastname: Liu
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects; D001249:Asthma / Q000378:metabolism / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004724:Endoscopy; D004804:Eosinophils / Q000473:pathology*; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000378:metabolism* / Q000473:pathology*; D010256:Paranasal Sinuses; D012852:Sinusitis / Q000378:metabolism / Q000473:pathology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D001241:Aspirin